Financial reports / International Stem Cell Corporation | Tables in SEC filings

ISCO International Stem Cell Corporation

Quarterly report

	September 30,		December 31,
	2024		2023
Assets
Current assets:
Cash	$	1,307	$	1,588
Accounts receivable, net		680		574
Inventories		1,384		1,263
Prepaid expenses and other current assets		119		96
Total current assets		3,490		3,521
Non-current inventories		223		266
Property and equipment, net		290		215
Intangible assets, net		739		800
Right-of-use assets		407		557
Deposits and other assets		31		31
Total assets	$	5,180	$	5,390
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Deficit
Current liabilities:
Accounts payable	$	321	$	364
Accrued liabilities		475		485
Operating lease liabilities, current		315		276
Advances		250		250
Related party note payable		3,357		3,457
Total current liabilities		4,718		4,832
Operating lease liabilities, net of current portion		203		445
Total liabilities		4,921		5,277
Commitments and contingencies (Note 8)
Series D redeemable convertible preferred stock, $0.001 par value; 50 shares authorized; 43 shares issued and outstanding; liquidation preference of $4,300 at September 30, 2024 and December 31, 2023		4,300		4,300
Stockholders' Deficit:
Non-redeemable convertible preferred stock, $0.001 par value; 10,004,310 and 10,004,310 shares authorized; 5,254,310 and 5,254,310 shares issued and outstanding; liquidation preference of $9,808 and $9,796 at September 30, 2024 and December 31, 2023, respectively		5		5
Common stock, $0.001 par value; 120,000,000 shares authorized; 8,004,389 shares issued and outstanding at September 30, 2024 and December 31, 2023		8		8
Additional paid-in capital		106,642		106,276
Accumulated deficit		(110,696)		(110,476)
Total stockholders' deficit		(4,041)		(4,187)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	$	5,180	$	5,390

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Skin care products	$	179	$	188	$	596	$	621

			Shares
	Shares		Issued and		Liquidation		Carrying
	Authorized		Outstanding		Preference		Value
					(in thousands)
Series B		5,000,000		250,000	$	498	$	—
Series G		5,000,000		5,000,000		5,000		5
Series I-2		4,310		4,310		4,310		—
Total		10,004,310		5,254,310	$	9,808	$	5

					Average
			Weighted-		Remaining		Aggregate
	Number of		Average		Contractual		Intrinsic
	Outstanding		Exercise		Term		Value
	Options		Price		(in years)		(in thousands)
Outstanding at December 31, 2023		11,807,494	$	0.64
Granted		782,222	$	0.12
Forfeited or cancelled		(50,000)	$	1.53
Expired		(15,304)	$	23.25
Outstanding at September 30, 2024		12,524,412	$	0.58		7.19	$	—
Vested and expected to vest at September 30, 2024		12,200,632	$	0.59		7.15	$	—
Exercisable at September 30, 2024		8,853,302	$	0.75		6.46	$	—

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Product sales	$	2,179	$	1,973	$	6,639	$	5,900
Operating expenses:
Cost of sales		974		781		2,774		2,318
General and administrative		816		832		2,609		2,550
Selling and marketing		292		302		928		926
Research and development		187		155		447		345
Total operating expenses		2,269		2,070		6,758		6,139
Loss from operations		(90)		(97)		(119)		(239)
Other income (expense):
Interest expense		(35)		(34)		(106)		(105)
Other income		—		—		5		8
Employee retention credit		—		—		—		663
Total other income (expense), net		(35)		(34)		(101)		566
Net income (loss)		(125)		(131)		(220)		327
Undistributed earnings allocated to participating securities		—		—		—		(155)
Net income (loss) allocable to common stockholders	$	(125)	$	(131)	$	(220)	$	172
Net income (loss) per common share, basic and diluted	$	(0.02)	$	(0.02)	$	(0.03)	$	0.02
Weighted-average common shares used to compute net income (loss) per share, basic and diluted		8,004,389		8,004,389		8,004,389		8,004,389

Table search / Financial reports / International Stem Cell Corporation

101 results

Top filers

Top filing types

Recent filing years